Beyond Recovery: UK Biotech Talent in a changing world
Recover is not the same as restoration
On the surface, the latest BIA numbers on UK life sciences investment are very encouraging after several lean years.
In Q2 2026 UK biotech secured £2.11 billion in total equity financing with £2.05 billion in venture capital. It was the strongest VC quarter in five years and the UK attracted around 61 per cent of European biotech venture funding.
Look closer and the picture is nuanced.
A single round in Isomorphic Labs accounted for £1.6 billion of that total. Excluding that landmark deal, UK biotech companies raised £498 million in venture capital in the quarter. This was still almost double the £279 million recorded in Q2 2025 and a real improvement on last year, but it’s not a rising tide that lifts all boats.
Patent and investment commentators describe a market shaped by “hyper selectivity of capital”. Early stage companies that once raised money on strong hypotheses and promising early data now find it significantly harder to secure backing. Investors concentrate on clear clinical differentiation and carefully considered got-to-market strategy.
In that context, it’s no surprise that the lived experience of scientists and leaders does not yet feel like recovery. Over the last year or two, we’ve seen a substantial number of roles cut from UK companies. This pattern has not yet reversed. We continue to see:
Wet lab scientists and experienced managers out of work for six months or more
Redundancies and restructuring that remove laboratory roles permanently
Hiring processes that involve many interview stages and end without appointment
Of course some of these roles will return as capital flows through into hiring. It is unlikely that all of them will.
Even in recovery, the old structure is not coming back in full.
Capital discipline and the future of lab work
The last three years have taught founders, boards and investors hard lessons about burn rate and financing risk. In the next cycle, companies are unlikely to rebuild large internal wet lab teams in the way they did in the easy money years.
Instead, many will keep internal teams smaller and more focused. They’ll retain scientific leadership, programme design and critical know how in house, of course, but will increasingly look to use external execution capacity more aggressively to extend runway and de risk programmes.
This is not an argument that lab science is less important. It is an observation that more of the hands on experimental work can and will be carried out through networks of CROs and CDMOs, academic partners and international laboratories.
For the UK, the question is not whether every scientist should be employed in a UK based company. It is whether enough of the high value parts of the system remain here:
Programme ownership and scientific leadership
Translational judgement and regulatory strategy
Quality oversight and risk management
Commercial decision making and value capture
If those remain in British hands, a more distributed laboratory footprint need not mean a weaker UK sector.
The problem arises if work moves and the capability to direct it does not.
China as a non clinical and early science power
China is becoming a central player in this more distributed model, not just as a low cost option, but as a very real option for non clinical development and early de risking of science.
Over the last decade China has invested heavily in innovative drug R&D. Regulatory reforms, improved clinical trial infrastructure and targeted funding have helped move activity beyond me too products and low cost generics. Chinese organisations are increasingly visible in areas such as oncology, autoimmune disease, complex biologics and cell and gene therapies.
The country has also built significant capacity in:
Discovery and preclinical biology
High throughput screening and hit to lead work
In vivo pharmacology and toxicology
Process development and early biomanufacturing
At the same time, there is an active and growing CRO and CDMO sector. This supports rapid non clinical development, generates data that can help de risk projects before large clinical commitments and can often do so at lower cost than Western providers.
Many have and will continue to point to perceived risks and constraints around IP, data, export controls and geopolitics. Some areas of science and technology, they will argue, will be inappropriate for China based work. Some datasets and platforms will need to remain firmly under UK control.
None of that changes the basic point. China is now a serious global player in non clinical development and early science, and UK companies will increasingly consider it as part of their option set.
The differentiated scientist
This is where the talent question becomes strategic.
If the UK is moving toward a model with:
A more selective funding environment
Fewer large internal wet lab teams
Greater use of external and international laboratory capacity
Then some traditional laboratory roles will not fully return, even in better times. The UK will still need excellent bench scientists, but it will need relatively more people who can:
Decide what to keep in house and what to send out
Select and oversee external partners
Manage quality, timelines and technical risk across borders
Protect IP and data while still getting the work done
Interpret results in context and make the next decision
The differentiated candidate in that world is not only the scientist with impeccable internal track records. It is the person who has taken their skills into another major ecosystem, seen how things work on the ground, and come back with practical knowledge and relationships.
For a UK wet lab scientist who is between roles today, it is worth asking a hard question.
Would you be better served waiting twelve months for the perfect UK vacancy to appear, or by spending twelve to eighteen months in Shanghai or another Chinese hub, learning how science is actually executed there?
Not simply to secure a short term job, and not simply to add a line to a CV, but to:
Understand how Chinese non clinical development and CRO models really operate
Build judgement about quality and reliability of individual companies rather than rely on guess work or second hand information
See first hand what can be done quickly and what cannot
Form relationships with scientists, managers and founders that do not show up in pitch decks
The person who comes back with that experience can support UK investors and companies as they decide when and how to use Chinese capacity. They can move into roles that sit at the interface between UK strategy and global execution, whether in R&D operations, BD and partnering, technical project leadership or specialist advisory work.
In other words, they become a bridge between UK innovation and Chinese capacity, rather than a casualty of a changing market.
Spend any time in China and you’ll hear the same point come up again and again; China’s rapid explosion from generic partner to leader of innovation was greatly supported by American Chinese returning back to China, bringing key knowledge of the US and global biotech environment back with them. It’s a proven model, and one of the many things we could learn and replicate.
What this implies for UK policy
If we accept that recovery will not restore the old structure, then policy needs to catch up.
First, we should stop treating every international move as loss. Well designed mobility can be a way of building capability that the UK will need if it is to lead in a world of distributed R&D.
Second, there is a case for a small, tightly defined UK China talent pilot. That could provide structured twelve to eighteen month placements in high quality Chinese organisations, paired with agreed routes back into UK roles. The focus should be on non clinical development, early science de risking and external R&D management, not generic exchange, with a particular view to developing good understanding of the Chinese ecosystem.
Third, we should recognise that some jobs will not return and plan for scientists to move into higher leverage roles rather than out of the sector. That means supporting transitions from pure bench work to programme leadership, vendor oversight, translational coordination and cluster or investor facing roles.
Finally, we should measure what really matters. Headcount is one indicator. Ownership of programmes, control over key decisions and the presence of people who can direct global networks are at least as important.
UK biotech can and will fly again. The science base, the clusters and the investor interest are still there. But the next phase will be built on a different structure. We should be honest that some parts of the industry will never look the same and we should help scientists move into the roles that the new model will prize most highly.
The scientists who choose to understand China from the inside, then come back and use that knowledge to shape how UK capital engages there, will very well placed.